Print

Kalypsys, Inc. Initiates Phase IIa Clinical Trial of Topical iNOS Inhibitor  
12/18/2007 2:13:37 PM

SAN DIEGO--(BUSINESS WIRE)--Kalypsys Inc. today announced the initiation of a Phase IIa clinical trial of KD7040, an inducible nitric oxide synthase (iNOS) inhibitor formulated as a topical gel, for the treatment of postherpetic neuralgia (PHN).
//-->